Is Alzheimer’s drug donanemab really a 'turning point' for treatment?
The experimental drug donanemab slows the progression of Alzheimer's disease compared with a placebo, but the effect may not be large enough to be noticed by people with the condition or their families
The experimental drug donanemab slows the progression of Alzheimer's disease compared with a placebo, but the effect may not be large enough to be noticed by people with the condition or their families
What's Your Reaction?
SIN
ScienceX Information Network (SIN) | ScienceX Innovations
